External adjustment for unmeasured confounders improved drug-outcome association estimates based on health care utilization data

Journal of Clinical Epidemiology

Volumn 65, Issue 11, 2012, Pages 1190-1199

  Corrao, Giovanni ^a   Nicotra, Federica ^a   Parodi, Andrea ^a   Zambon, Antonella ^a   Soranna, Davide ^a   Heiman, Franca ^b   Merlino, Luca ^c   Mancia, Giuseppe ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b BKL Consulting Srl ^*  (Italy)

^c Operative Unit of Territorial Health Services   (Italy)

Author keywords

Antihypertensive drugs; Bias; Combined therapy; Monotherapy; Monte Carlo sensitivity analysis; Observational studies; Pharmacoepidemiology; Unmeasured confounding

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADJUSTMENT; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHRONIC DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; HYPERTENSION; ITALY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICAL RECORD; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TABLET;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BIAS (EPIDEMIOLOGY); CARDIOVASCULAR DISEASES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DATABASES AS TOPIC; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC METHODS; FEMALE; HEALTH SERVICES; HUMANS; HYPERTENSION; ITALY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACOEPIDEMIOLOGY;

EID: 84866843285     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2012.03.014     Document Type: Article

References (37)

1. B.L. Strom Overview of automated databases in pharmacoepidemiology B.L. Strom, Pharmacoepidemiology 4th ed. 2005 Wiley New York, NY 219 222
2. S. Schneeweiss Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics Pharmacoepidemiol Drug Saf 15 2006 291 303
3. G. Mancia, S. Laurent, E. Agabiti-Rosei, E. Ambrosioni, M. Burnier, and M.J. Caulfield Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document J Hypertens 27 2009 2121 2158
4. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure National High Blood Pressure Education Program Coordinating Committee The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2003 2560 2572
5. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
6. M.R. Law, N.J. Wald, J.K. Morris, and R.E. Jordan Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials BMJ 326 2003 1427 1434
7. D.S. Wald, M. Law, J.K. Morris, J.P. Bestwick, and N.J. Wald Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials Am J Med 122 2009 290 300
8. A.J. Claxton, J. Cramer, and C. Pierce A systematic review of the associations between dose regimens and medication compliance Clin Ther 23 2001 1296 1310
9. A.K. Gupta, S. Arshad, and N.R. Poulter Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis Hypertension 55 2010 399 407
10. S. Bangalore, G. Kamalakkannan, S. Parkar, and F.H. Messerli Fixed-dose combinations improve medication compliance: a meta-analysis Am J Med 120 2007 713 719
11. B. Dahlof, P.S. Sever, N.R. Poulter, H. Wedel, D.G. Beevers, M. Caulfield ASCOT Investigators Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial Lancet 366 2005 895 906
12. S. Greenland Basic methods for sensitivity analyses of biases Int J Epidemiol 25 1996 1107 1116
13. D. Kriebel, A. Zeka, E.A. Eisen, and D.H. Wegman Quantitative evaluation of the effects of uncontrolled confounding by alcohol and tobacco in occupational cancer studies Int J Epidemiol 33 2004 1040 1045
14. K. Steenland, and S. Greenland Monte Carlo sensitivity analysis and Bayesian analysis of smoking as an unmeasured confounder in a study of silica and lung cancer Am J Epidemiol 160 2004 384 390
15. G. Corrao, G. Cesana, and L. Merlino Pharmacoepidemiological research and the linking of electronic healthcare databases available in the Italian region of Lombardy BioMed Stat Clin Epidemiol 2 2008 117 125
16. H. Tunstall-Pedoe, K. Kuulasmaa, P. Amouyel, D. Arveiler, A.M. Rajakangas, A. Pajak for the WHO MONICA Project Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents Circulation 90 1994 583 612
17. K. Asplund, R. Bonita, K. Kuulasmaa, A.M. Rajakangas, H. Schaedlich, and K. Suzuki Multinational comparisons of stroke epidemiology: evaluation of case ascertainment in the WHO MONICA stroke study Stroke 26 1995 355 360
18. N.E. Breslow, and N.E. Day Statistical methods in cancer research. Vol. I. The analysis of case-control studies IARC Scientific Publications N° 32 1980 International Agency for Research on Cancer Lyon, France
19. S. Greenland, J. Pearl, and J.M. Robins Causal diagrams for epidemiologic research Epidemiology 10 1999 37 48
20. S. Schneeweiss, R.J. Glynn, E.H. Tsai, J. Avorn, and D.H. Solomon Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information. The example of Cox2 inhibitors and myocardial infarction Epidemiology 16 2005 17 24
21. G. Mazzaglia, L. Mantovani, M.C. Sturkenboom, A. Filippi, G. Trifiro, and C. Cricelli Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care J Hypertens 23 2005 2093 2100
22. G. Mazzaglia, E. Ambrosioni, M. Alacqua, A. Filippi, E. Sessa, and V. Immordino Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients Circulation 120 2009 1598 1605
23. G. Corrao, A. Parodi, A. Zambon, F. Heiman, A. Filippi, and C. Cricelli Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice J Hypertens 28 2010 1584 1590
24. A.M. Walker Confounding by indication Epidemiology 7 1996 335 336
25. D.R. Berlowitz, and S. Franklin The clock is ticking: the case for achieving more rapid control of hypertension J Clin Hypertens 12 2010 323 327
26. M.R. Weir, D. Levy, N. Crikelair, R. Rocha, X. Meng, and R. Glazer Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy Am J Hypertens 20 2007 807 815
27. J.M. Neutel, E. Saunders, G.L. Bakris, W.C. Cushman, K.C. Ferdinand, and E.O. Ofili The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial J Clin Hypertens (Greenwich) 7 2005 578 586
28. K. Jamerson, G.L. Bakris, B. Dahlöf, B. Pitt, E. Velazquez, and J. Gupte Exceptional early blood pressure control rates: the ACCOMPLISH trial Blood Press 16 2007 80 86
29. S. Julius, S.E. Kjeldsen, M. Weber, H.R. Brunner, S. Ekman, L. Hansson VALUE trial group Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 363 2004 2022 2031
30. J.A. Staessen, J.G. Wang, and L. Thijs Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003 J Hypertens 21 2003 1055 1076
31. P. Verdecchia, G. Reboldi, F. Angeli, R. Gattobigio, M. Bentivoglio, and L. Thijs Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention Hypertension 46 2005 386 392
32. K. Miura, M.L. Daviglus, A.R. Dyer, K. Liu, D.B. Garside, and J. Stamler Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry Arch Intern Med 161 2001 1501 1508
33. B.M. Psaty, C.D. Furberg, L.H. Kuller, M. Cushman, P.J. Savage, and D. Levine Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study Arch Intern Med 161 2001 1183 1192
34. S. Perreault, A. Dragomir, M. White, L. Lalonde, L. Blais, and A. Berard Better adherence to antihypertensive agents and risk reduction of chronic heart failure J Intern Med 266 2009 207 218
35. M.A. Hernan, and J.M. Robins Letter to the editor. Assessing the sensitivity of regression results to unmeasured confounders in observational studies Biometrics 55 1999 1316 1317
36. G. Corrao, A. Zambon, A. Parodi, M. Mezzanzanica, L. Merlino, and G. Cesana Do socioeconomic disparities affect accessing and keeping antihypertensive drug therapy? Evidence from a Italian population-based study J Hum Hypertens 23 2009 238 244
37. G. Corrao, A. Zambon, F. Nicotra, C. Fornari, C. La Vecchia, and M. Mezzanzanica Persistence with oral and transdermal hormone replacement therapy and hospitalisation for cardiovascular outcomes Maturitas 57 2007 315 324